Novo Nordisk A/S (NYSE:NVO) on Saturday presented new phase 3 data supporting the long-term safety and efficacy of investigational hemophilia A treatment denecimig (Mim8).
• Novo Nordisk shares are consolidating. What’s ahead for NVO stock?
The company said the findings further strengthen its hemophilia portfolio as denecimig remains under U.S. Food and Drug Administration (FDA) review following a Biologics License Application submitted in September 2025.
Long-Term Data Reinforces Denecimig’s Safety and Bleeding Control
The interim analysis from the open-label Phase 3 FRONTIER4 extension study included 426 patients aged one year and older with hemophilia A, including individuals with and without inhibitors.
Participants received denecimig prophylaxis through once-monthly, once-every-two-weeks, or once-weekly dosing regimens.
For the primary safety endpoint, denecimig’s profile remained consistent with previous FRONTIER studies.
Injection-site reactions occurred in 2.0% of injections in children and 1.8% in adolescents and adults, with all events reported as mild and transient. The company also reported no clinical evidence of neutralizing antibodies.
On efficacy, estimated mean annualized bleeding rates remained low across all dosing schedules and regardless of inhibitor status.
Adults and adolescents recorded an estimated mean annualized bleeding rate of 0.75, while children posted a rate of 0.37. Approximately 71% of adults and adolescents and 89% of children experienced zero treated bleeds during treatment.
Patient Experience and Clotting Data Support Clinical Findings
Novo Nordisk said exploratory patient-reported outcomes showed long-term improvements seen in earlier FRONTIER studies were maintained. Patients aged 12 years and older continued to report reduced joint pain, while participants across age groups experienced a lower treatment burden.
Among 185 respondents, more than 94% rated the denecimig pen injector as easy or very easy to use, and nearly 90% said it was quick or very quick to prepare and inject.
Separately, post hoc analyses from the Phase 3 FRONTIER2 and FRONTIER5 studies found denecimig increased thrombin generation into the normal reference range in adolescents and adults without producing an excessive clotting response.
Concizumab Data Shows Lower Bleeding Rates In Children
Novo Nordisk also reported first-time results from the Phase 3 explorer10 trial evaluating concizumab prophylaxis in 24 children younger than 12 years with hemophilia A or B with inhibitors.
The company said concizumab reduced the estimated mean annualized bleeding rate to 2.08 from 11.51 with prior on-demand treatment, representing an 82% reduction.
While 83% of participants experienced at least one treatment-emergent adverse event, most were mild and resolved.
Injection-site reactions remained infrequent, although 29% of participants reported serious adverse events.
NVO Stock Price Activity: Novo Nordisk shares were down 0.091% at $49.43 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
Login to comment